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The  utilization  of  nutrients  from  the  environment  by 
normal  cells  is  controlled  by  fine-tuned  mechanisms 
regulated by growth factor signals. Cancer cells overcome 
this  growth  factor  dependence  by  acquiring  genetic 
mutations that rewire signaling pathways that affect the 
uptake of nutrients, and reprogram metabolism to fuel 
the  biosynthetic  processes  required  to  support  their 
altered  cell  growth,  survival  and  proliferation  [1].  This 
rewiring for growth may make tumors more vulnerable 
to nutrient deprivation, however. For instance, growing 
evidence demonstrates that cancer-promoting mutations 
result in addiction to nutrients, particularly glucose. In 
an article in Cell and Bioscience, Jiang et al. [2] explore 
the therapeutic potential of glucose deprivation, by both 
pharmacological and dietary means, in a rodent model of 
tuberous sclerosis complex-related tumors, which display 
glucose addiction in vitro.
The glucose appetite of tumors and its regulation 
by mTORC1
Research efforts have sought to characterize tumor cell 
metabolism  since  Otto  Warburg’s  observations  in  the 
1920s  of  the  tendency  of  cancer  cells  to  metabolize 
glucose  into  lactate  despite  sufficient  oxygen  levels 
(known as the Warburg effect or ‘aerobic glycolysis’). By 
contrast,  most  differentiated  cells  primarily  metabolize 
glucose to carbon dioxide by oxidation of pyruvate in the 
mitochondrial tricarboxylic acid (TCA) cycle, a process 
known as oxidative phosphorylation that requires far less 
glucose  to  generate  the  same  amount  of  energy.  The 
heightened appetite of tumor cells for glucose has been 
put to diagnostic use, as high rates of glucose utilization 
can be detected using [18F]-fluorodeoxyglucose positron 
emission  tomography  (FDG-PET),  providing  images  in 
which tumors often appear as PET-positive as the most 
metabolically active tissues. Understanding why and how 
the Warburg effect occurs has posed a puzzle, however, 
as it is not immediately obvious why aerobic glycolysis 
should be favored in tumors when it is an inefficient way 
to generate energy. It is thought that the Warburg effect 
supports tumor growth by diverting glucose to macro-
molecular precursors, such as acetyl-coA for fatty acids, 
glycolytic  intermediates  for  nonessential  amino  acids, 
and ribose for nucleotides [3].
In  normal  cells  the  switch  from  a  non-proliferating 
state, in which oxidative phosphorylation meets the cell’s 
energy needs, to proliferation, in which glycolysis domi-
nates, is triggered by growth factors acting through the 
mammalian Target of Rapamycin Complex 1 (mTORC1) 
signaling pathway (Figure 1). This pathway allows cells to 
integrate  information  about  environmental  conditions 
and to balance catabolic and anabolic processes accord-
ingly. Growth factor-activated kinases phosphorylate and 
inhibit the tumor sclerosis complex TSC1-TSC2, allowing 
the  small  G  protein  Rheb  to  activate  mTORC1.  In 
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http://www.biomedcentral.com/1741-7007/9/69addition,  mTORC1  is  sensitive  to  intracellular  energy 
levels  through  the  AMP-activated  protein  kinase 
(AMPK).  In  response  to  energy  depriva  tion,  AMPK 
phosphorylates  TSC2,  and  the  mTORC1  component 
raptor, resulting in mTORC1 inhibition and a reduction 
of  energy  consumption  [4]  (Figure  1).  The  most 
recognized  function  for  mTORC1  is  the  promotion  of 
protein synthesis through the phosphorylation of at least 
two direct downstream targets, the ribosomal S6 kinases 
(S6K1  and  S6K2),  and  the  translation  repressors 
eIF4E-binding proteins 1 and 2 (4E-BP1 and 4E-BP2) [4] 
(Figure 1). However, studies using the mTORC1-specific 
inhibitor  rapamycin  have  revealed  a  broader  role  of 
mTORC1  in  regulating  the  metabolic  processes  that 
support cell growth and proliferation (Figure 2).
In addition to driving protein synthesis, activation of 
mTORC1 promotes glycolysis by up-regulating Hypoxia-
inducible  factor  (HIF1α)  and  c-Myc,  which  in  turn 
promote  the  expression  of  proteins  involved  in  nearly 
every step of the glycolytic pathway. mTORC1 activation 
Figure 1. A network of oncogenes and tumor suppressors regulates the mTORC1-signaling pathway. Growth factors bind and stimulate 
receptor tyrosine kinases (RTKs), which can activate both the PI3K-Akt and Ras-ERK signaling pathways. These upstream signals inhibit the 
TSC1-TSC2 complex allowing Rheb to activate mTORC1. Activated mTORC1 phosphorylates two direct substrates, the ribosomal S6 kinases (S6K1 
and S6K2), and translation repressors 4E-BP1 and 4E-BP2. Cellular energy depletion results in the activation of AMP-activated protein kinase (AMPK) 
by the tumor suppressor protein LKB1 serine/threonine kinase. AMPK phosphorylates and enhances the GAP function of TSC2 towards Rheb. In 
addition, AMPK directly phosphorylates the mTORC1 component raptor. Both events result in the inhibition of mTORC1 in response to energy 
stress. Within this signaling network lie many oncogenes (depicted in red) and tumor suppressors (depicted in blue).
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Page 2 of 5also  contributes  to  the  Warburg  effect  by  diverting 
pyruvate away from oxidation in mitochondria. This is 
achieved  by  increased  expression  of  lactate  dehydro-
genase, which converts pyruvate to lactate, and pyruvate 
dehydrogenase kinase, which inhibits the conversion of 
pyruvate to acetyl-CoA. Furthermore, mTORC1 stimu-
lates de novo lipogenesis by promoting the expression of 
genes regulated by the sterol regulatory element-binding 
protein (SREBP1), thereby promoting the synthesis of the 
fatty acids needed for new cell membranes. Interestingly, 
mTORC1  activation  is  also  sufficient  to  stimulate  the 
expression  of  genes  encoding  the  enzymes  involved  in 
the pentose phosphate pathway (PPP), including glucose 
6-phosphate  dehydrogenase  (G6PD)  in  an  SREBP1-
dependent manner. Activation of the PPP provides cells 
with sources of NADPH to drive anabolic metabolism, as 
well as the generation of ribose 5-phosphate for de novo 
nucleotide biosynthesis [5] (Figure 2). It remains to be 
determined  whether  the  mTORC1  pathway  influences 
the metabolism of glutamine (glutaminolysis), an abun-
dant nutrient essential for cancer cell bioenergetics and 
proliferation. It is known that c-Myc can stimulate gluta-
mine catabolism [6], however, suggesting that mTORC1-
dependent regulation of c-Myc promotes glutaminolysis 
as well as glycolysis.
In sum, the various metabolic outcomes of activating 
the mTORC1 pathway render cells dependent on glucose 
and  perhaps  glutamine  to  support  their  biosynthetic 
needs for rapid growth and proliferation. In normal cells, 
mTORC1 activation is regulated in accordance with the 
Figure 2. The mTORC1 pathway controls cellular metabolism. The mTORC1 signaling pathway controls metabolic pathways active in 
proliferating cells. This schematic shows our current understanding of how glycolysis, oxidative phosphorylation, the pentose phosphate pathway 
(PPP), and glutamine metabolism are interconnected in proliferating cells. The mTORC1 pathway participates in this metabolic rewiring by 
controlling the expression of genes (depicted in blue) encoding enzymes involved in glycolysis, the PPP, and lipid synthesis. This metabolic control 
requires the up-regulation of c-Myc and HIF1α (glycolysis), and SREBP1 (lipid biosynthesis and the PPP). mTORC1-dependent metabolic regulation 
allows for production of both NADPH and intermediates for macromolecular synthesis (depicted in red). c-Myc drives glutamine metabolism, which 
also supports NADH production.
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Page 3 of 5needs of the organism, but in cancer cells, mutations in 
various oncogenes or tumor suppressors can lead to its 
aberrant activation (Figure 1). In TSC-related tumors the 
loss of the TSC1/2 complex leads to mTORC1 activation 
irrespective of growth factor or energy levels, and also to 
reduced insulin-stimulated glucose uptake [7], resulting 
in an impaired ability to balance metabolic demand with 
supply. Whether the consequent hypersensitivity of TSC-
related tumors to glucose deprivation that is observed in 
vitro  [8]  can  be  exploited  therapeutically  in  vivo  is 
addressed by the study of Jiang et al. [2].
The glucose addiction of TSC-mutant tumors as a 
therapeutic target
TSC is an autosomal dominant genetic disease with an 
incidence  of  1  in  6,000  at  birth,  and  nearly  1,000,000 
people worldwide are known to have TSC. TSC is due to 
genetic  inheritance  or  spontaneous  inactivating  muta-
tions in either TSC1 or TSC2 genes, and is characterized 
by the formation of non-invasive benign tumors in many 
organs.
Rapamycin  and  its  analogues,  because  of  their 
inhibitory  effect  on  the  mTORC1  pathway,  have  been 
examined as potential therapeutic agents in the treatment 
of TSC; however, early studies have demonstrated that 
while  these  drugs  can  reduce  tumor  size,  the  tumors 
return  after  treatment  stops  [9].  Therefore,  identifying 
new  therapeutic  options  that  can  specifically  eliminate 
TSC tumors remains an important goal. Targeting cellular 
metabolism has received particular attention during the 
past  few  years  as  an  alternative  strategy  for  cancer 
therapy,  and  could  prove  an  important  approach  for 
treating TSC based on the rationale that TSC1/2-/- cells 
require glucose for survival [8].
The research of Jiang et al. [2] sought to examine the 
effects  of  the  glycolytic  inhibitor  2-deoxy-d-glucose 
(2-DG) and a diet free of carbohydrates on the growth of 
LEF2 cells from a Tsc2-null rat tumor implanted in mice. 
The exposure of these cells to 2-DG resulted in decreased 
cell  viability  at  low  glucose  concentration.  2-DG  is  an 
analog of glucose in which the 2-hydroxyl group has been 
replaced by hydrogen, thus preventing it from undergoing 
glycolysis. This leads to reduced cellular ATP levels and 
subsequently  cell  growth.  Jiang  et  al.  show  that  2-DG 
treatment  suppresses  tumor  growth  by  reducing  cell 
proliferation in this model, although they did not show 
whether this is accompanied by apoptosis as occurs in 
vitro  [2].  These  observations  suggest  that  2-DG  is  a 
promising antitumor therapy and, in fact, this compound 
is being used to treat osteosarcomas and lung cancers in 
phase II clinical trials. However, pre-trial studies show 
that 2-DG, as is the case with other glycolysis inhibitors, 
does not have a significant effect on tumor growth when 
used  on  its  own  as  a  monotherapy,  although  it  can 
sensitize  tumors  to  chemotherapeutic  agents  such  as 
paclitaxel [10]. The differences between previous studies 
and the results shown by Jiang et al. raise the question of 
whether  2-DG  effects  are  dependent  on  the  type  of 
tumor,  and  if  this  could  be  specifically  related  to  the 
hyper  sensitivity of TSC2-/- tumors to glucose deprivation.
Jiang  et  al.  also  tested  the  effects  of  a  diet  free  of 
carbohydrates in their model, anticipating that this would 
also deprive the TSC2-/- tumors of glucose, and add to 
the  effects  of  2-DG.  However  their  diet  (which  was 
carbohydrate-free  but  not  calorie-restricted)  produced 
some unexpected results. In humans a carbohydrate-free 
diet  leads  to  reduced  blood  glucose  and  an  increased 
production  of  ketone  bodies  as  nutrients  other  than 
glucose are used to produce energy [11], but in the mice 
fed with a carb-free diet in the study of Jiang et al. levels 
of  β-hydroxybutyrate  (HOB),  a  ketoacid,  were  not 
affected and blood glucose remained high [2]. Strikingly, 
and in contrast to the results of 2-DG treatment, this diet 
resulted  in  larger  tumors  with  increased  necrosis  and 
zones of liquefaction. These large tumors did not appear 
to be fueled by glucose, however, as the diet was effective 
in  decreasing  the  uptake  of  [18F]-fluorodeoxyglucose 
(FDG),  suggesting  that  nutrient  sources  other  than 
glucose are fuelling anabolism and survival under these 
conditions [2].
The carb-free diet provides abundant fatty acids that 
are  broken  down  by  beta-oxidation  into  acetyl-CoA,  a 
major  substrate  for  energy  and  biomass  production 
through  the  TCA  cycle.  Interestingly,  a  recent  report 
demonstrates  that  high-grade  primary  tumors  contain 
elevated  levels  of  fatty  acids  that  contribute  to  the 
proliferation of aggressive cancer cells by increasing the 
levels of signaling lipids such as phosphatidic acid, lyso-
phosphatidic acid and prostaglandin E2 [12]. Consistent 
with this, Jiang et al. [2] show that treatment of LEF2 cells 
with  oleic  acid  results  in  increased  proliferation  and 
survival. In contrast, treatment with the saturated palmitic 
acid induces apoptosis in LEF2 cells, an observation that 
might  be  relevant  to  the  increased  areas  of  necrosis 
observed in the tumors of carb-free fed mice [2].
While the carb-free diet failed to inhibit TSC tumor 
progression,  the  2-DG  effects  on  tumor  growth  are 
promising  and  encouraging  for  future  clinical  trials  in 
TSC patients. However, toxicity due to off-target effects 
has been attributed to this compound in clinical trials, 
and three of ten mice in this study were sacrificed early 
on  account  of  weight  loss  during  2-DG  treatment  [2], 
suggesting  that  there  are  inherent  difficulties  in  an 
approach  that  attempts  to  starve  a  tumor  but  not  the 
organism that hosts it. One way of overcoming toxicity 
problems while improving efficacy is to use combination 
therapies,  and  for  TSC-related  tumors  there  are  good 
reasons to consider these in future studies. TSC tumors 
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increased glycolytic flux [13], suggesting that a glucose-
independent nutrient source is fueling the cells. More-
over,  recent  work  has  demonstrated  that  glutamine  is 
required to maintain the cellular bioenergetics of TSC-/- 
cells [14]. Therefore combination therapies targeting both 
glutamine and glucose addiction might be effective.
Cancer  therapy  is  increasingly  shifting  toward  indi-
vidualized therapeutic approaches based on the genetic 
abnormalities exhibited by transformed cells. Jiang et al. 
[2]  demonstrate  that  targeting  glucose  addiction  is  an 
effective approach for decreasing the growth of tumors 
driven by TSC mutations. Thus glucose addiction may 
prove to be the ‘Achilles’ heel’ for the treatment of TSC. 
Whether  these  findings  will  translate  to  other  tumor 
types, in which the constitutive activation of mTORC1 is 
a result of different genetic abnormalities, and whether 
the toxic side effects of 2-DG can be overcome, however, 
remains to be seen.
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